Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-08-01
DOI
https://doi.org/10.1136/jitc-2025-012478
Citations
5
Primary Topic
Polyomavirus and related diseases
Type
article
Field-Weighted Citation Impact
5.23

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)

Jennifer Pulini, Mark Cornfeld, Célèste Lebbé, Shailender Bhatia et al.
5 citations
Journal for ImmunoTherapy of Cancer
Polyomavirus and related diseases
5.23
article

Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)

Jennifer Pulini, Mark Cornfeld, Célèste Lebbé, Shailender Bhatia, Henri Montaudié, Caroline Gaudy‐Marqueste, Giovanni Grignani, Michele Guida, Francesco Spagnolo, Cecilia C.S. Yeung, Federica Morano, Roberta Depenni, Francesca Spada, Melissa Amber Burgess, Chuan Tian, Piotr Rutkowski
article en
5 citations

Abstract

No abstract available for this paper.
Journal for ImmunoTherapy of CancerVol. 13(8)
University of Modena and Reggio Emilia (IT), Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Côte d'Azur (FR), Université Paris Cité (FR), Aix-Marseille Université (FR), Centre Hospitalier Universitaire de Nice (FR), Fred Hutch Cancer Center (US), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), National Institute of Oncology (HU), UPMC Hillman Cancer Center (US), Istituto Tumori Bari (IT), Ospedale Policlinico San Martino (IT), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Candiolo Cancer Institute (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), European Institute of Oncology (IT), University of Genoa (IT), Incyte (United States) (US)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Fred Hutchinson Cancer Research Center, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Incyte, Advanced Accelerator Applications, Springworks Therapeutics, Eisai, Servier, PharmaMar, LEO Pharma, EMD Serono
Good health and well-being
Openalex Percentile: Top 4%
Polyomavirus and related diseases
5.23
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.